All partnering requests
Private Company
Weight management therapeutic solutions for companion animals
  • Background
  • What we're looking for
  • What we can offer you
  • Q&A
Have questions about this request?
Get them answered by the team at the company.
Background

Companion animal obesity is a common and growing health concern associated with reduced quality of life and increased risk of metabolic, orthopedic, and other chronic conditions. Weight management in dogs and cats has traditionally relied heavily on dietary modification, caloric restriction, increased activity, and behavioral management, but maintaining meaningful and sustained weight loss can remain challenging. 

 

At the same time, advances in metabolic disease, gut-hormone biology, and other areas are creating new approaches to weight loss and long-term weight management. Such therapeutic interventions may act through a wide range of mechanisms, from appetite and satiety pathways to energy expenditure, metabolism, and nutrient utilization. 

 

As innovation in this field expands, there is an opportunity to better understand the technologies and products being developed specifically for companion animals and to identify approaches with the potential to improve weight loss and weight management in dogs and cats.

What we're looking for

We are looking for technologies, products, and approaches that support weight loss and weight management in companion animals, particularly dogs and cats. We are open to therapeutics and other innovative solutions across mechanisms of action, whether commercially available or in development for companion-animal use.

Solutions of interest include:
  • Appetite and satiety modulators
  • GLP-1 and other incretin-based therapies
  • Gut-hormone and enteroendocrine modulators
  • Metabolic and energy-expenditure therapies
  • Thermogenesis and brown-fat activation approaches
Our must-have requirements are:
  • Preliminary data or a well-supported scientific rationale indicating potential to promote weight loss or support long-term weight management
  • Basic understanding of the underlying mechanism of action
  • For technologies developed primarily for other species, supporting evidence relevant to dogs and/or cats must be available (e.g., in vitro or ex vivo data, PK/PD, safety, target-expression, mechanistic, formulation, or other translational evidence)
Our nice-to-have's are:
  • Canine safety and tolerability data from relevant dosing studies
  • Supporting in vivo data in dogs, preferably demonstrating effects on weight loss, body composition, or long-term weight management
What's out of scope:
  • Behavior- or exercise-only interventions without a therapeutic, nutritional, or biologically active component
  • Microbiome and next-generation probiotic solutions
  • Nutritional supplements and functional ingredients
  • Other non-therapeutic interventions
  • Weight-management digital apps
Acceptable technology readiness levels (TRL):
Levels 5-9
What we can offer you
Eligible partnership models:
Co-developmentEquity investmentFee-for-serviceLicensingPilot or trial engagementSponsored researchSupply/purchase
Benefits:
Sponsored Research
Funding could range from $50,000 to $200,000 USD, including indirect costs, to support proof-of-concept, companion-animal efficacy or tolerability studies, product adaptation, or further evaluation.
Expertise
Partners may have access to experts in companion-animal metabolism, PK/PD, formulation, clinical studies, and product development.
Data
Where appropriate, relevant summary and technical insights may be shared to help guide study design, product evaluation, or development for dogs and cats.
Facilities and Services
Facilities and services may be available for companion-animal studies, sample collection and analysis, body-composition or metabolic assessments, and project-related data analysis.
Q&A with the company
Ask the team at the company any questions you have about this partnering request.
Ask your question
Sort by:
Q.
Hello! We have a first-in-class, small molecule drug that drives fat-targeted, muscle-preserving weight loss. We currently have mouse data. Would you be interested in partnering to develop the dog data?
2
A.
Dear Sobha: Thank you for reaching out. We are currently reviewing several opportunities across development stages. With that in mind, we are open to reviewing your proposal and welcome any additional information you are able to share. Our decision will be guided by several key factors, including the maturity of the asset, the depth and quality of available preclinical data, and the mechanism of action. We look forward to learning more about your program and understanding how it aligns with these criteria. Please feel free to share any supporting materials, and we will ensure it receives a thorough review. Best regards, The Review Team
Team Member, Reviewer, Private Company
November 12, 2026
Is this response helpful?
0
0
Sign up to access the full partnering request.
View the details of this request and connect directly with corporate R&D teams at Fortune 500 companies.
Submit Proposal
Deadline: November 27
Refine recommendations
Is this request relevant to you?
Eligible partners
Academic researchersConsultantsService providers (CROs/CMOs)StartupsSuppliers
Seeking partners focused on
AnatomyAgingAnimal ProductionBiochemistryBioinformaticsBiological ComplexityBiomimeticsBiomolecular ProcessesBiopharmaceuticsCarbohydrate Biochemistry
28 more

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.